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ABSTRACT: Lacticin 3147 is a two peptide lantibiotc 
(LtnA1 and LtnA2) that displays nanomolar activity 
against many Gram-positive bacteria. Lacticin 3147 may 
exert its antimicrobial effect by several mechanisms. 
Isothermal titration calorimetry experiments show that 
only LtnA1 binds to the peptidoglycan precursor lipid II, 
which could inhibit peptidoglycan biosynthesis. An 
experimentally supported model of the resulting 
complex that suggests the key binding partners are the 
C-terminus of LtnA1 and pyrophosphate of lipid II. A 
combination of in vivo and in vitro assays indicates that 
LtnA1 and LtnA2 can induce rapid membrane lysis 
without the need for lipid II binding. However, the 
presence of lipid II substantially increases the activity of 
lacticin 3147. Furthermore, studies with synthetic LtnA2 
analogues containing either desmethyl- or oxa-
lanthionine rings confirm that the precise geometry of 
these rings is essential for this synergistic activity. 
INTRODUCTION    
The continued emergence of antibiotic-resistant bacteria 
necessitates the discovery of novel antimicrobial 
compounds.1 In recent years, antimicrobial peptides 
(AMPs) have been the vanguard of new antimicrobial 
agents.2 Bacteriocins are a class of AMPs produced by 
bacteria that often display strong activity against 
pathogenic bacterial strains.3 The lantibiotics are a 
subclass of bacteriocins defined by their sulfur-containing 
rings, which result from the 1,4-conjugate addition of 
cysteine to dehydroalanine (lanthionine) or 
dehydrobutyrine (methyllanthionine) during their 
biosynthesis.4 Understanding the mechanism of action of 
antimicrobial compounds is important, as it can enable 
the rational design of more active and/or synthetically 
more accessible analogues.5 For lantibiotics, this can be 
achieved by chemical synthesis or genetic engineering.4-6 
A significant number of known AMPs bind to the 
peptidoglycan precursor lipid II. Peptidoglycan is 
structurally essential and unique to bacteria, and many 
antibiotics target this pathway.7 Lipid II binding AMPs 
can exert their antimicrobial effect through a variety of 
mechanisms. This includes inhibition of peptidoglycan 
biosynthesis (vancomycin, plectasin and teixobactin),8,9,2a 
disruption of the proton-motive-force (tridecaptin A1)10 
and membrane lysis/pore formation (lantibiotics).11   
   Lantibiotics are grouped into Type-A and -B peptides, 
based on their functional and structural features.12 Type-A 
lantibiotics are elongated, with similar arrangements of 
their thioether bridges. This group is subdivided into 
Type-A(I) and Type-A(II). Type-A(I) lantibiotics contain 
several charged residues and have a net negative or 
slightly positive charge whereas Type-A(II) lantibiotics 
are highly negatively charged. Type-B lantibiotics are 
typically shorter than Type-A and adopt a globular 
structure. Although these types differ considerably, 
examples from all types have been shown to bind lipid II.  
   Nisin (1) is a Type-A(I) lantibiotic routinely used in the 
food industry to protect against pathogenic Gram-positive 
bacteria (Figure 1).13 Nisin exerts its antimicrobial effect 
by pore formation on bacterial membranes, which is 
enhanced by the presence of lipid II,14 and binds to lipid 
II through its N-terminal lanthionine rings, forming a 
“pyrophosphate cage”.14d Mersacidin (2) is a Type-B 
lantibiotic that also binds to lipid II.15 2D-NMR 
experiments have shown that when lipid II is added to 
mersacidin, it undergoes several chemical shift 
perturbations in its C-terminus.15b There are also two 
component lantibiotic systems wherein one peptide binds 
to lipid II. These two component lantibiotics work 
synergistically to kill bacteria and include the 
haloduracins16 (Halα (3) and β (4)) and lacticin 3147 
(LtnA1 (5) and A2 (6)).17 Halα and LtnA1 are Type-B-
like lantibiotics with lanthionine bridging patterns (B, C 
and D rings) very similar to mersacidin. Mutations in 
these areas have been shown to reduce antimicrobial 
activity.18,19 Halβ and LtnA2 are both Type-A(I)-like 
lantibiotics with overall charges of +1. The similarities 
between mersacidin, Halα and LtnA1 are suggestive of a 
conserved lipid II binding motif.15,16    
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Figure 1. Bead structures of some lipid II-binding lantibiotics. Residues known or suspected to be involved in lipid II binding are 
light green. Lanthionine, methyl lanthionine and amino-vinyl-cysteine bridges are red. Type-A(I) = nisin (1); and Type-B = 
mersacidin (2). Haloduracin and Lacticin 3147 are two-component lantibiotics, in which Halα (3) and LtnA1 (5) are Type-B-like 
and bind to lipid II. Halβ (4) and LtnA2 (6) are type-A(I) like but do not bind to lipid II. Synthetic oxa-LtnA2 (7) and desMe-LtnA2 
(8) are also shown. 
   Lacticin 3147 is produced by Lactococcus lactis 
subspecies lactis DPC3147 and has broad-spectrum 
activity against Gram-positive bacteria.17 Previous 
mechanistic studies revealed that LtnA1 binds to lipid II 
on the surface of the cell membrane.20 It has been 
proposed that this complex then recruits LtnA2 and the 
resulting ternary complex inhibits cell wall synthesis and 
causes pore formation. Previous activity assays have 
shown that LtnA1 and LtnA2 operate in a 1:1 
stoichiometry.17d Our group has previously synthesized 
oxa- and desmethyl-lanthionine analogues of LtnA2 (oxa-
LtnA2 (7) and desMe-LtnA2 (8)), wherein lanthionine 
sulfurs are replaced with oxygen or methyls are missing 
from methyllanthionine residues, respectively.21,22 We 
also completed the first total syntheses of LtnA1 and 
LtnA2.23 Mechanistic studies on other lipid II binding 
peptides inspired us to study the mechanism of action of 
lacticin 3147 and the structure of the LtnA1 interaction 
with lipid II.10 
RESULTS AND DISCUSSION 
Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) is commonly used 
to assess the lipid II binding properties of antimicrobial 
peptides.24,25,10 We used ITC to study the interactions 
between natural and synthetic analogues of lacticin 3147 
  
Figure 2. ITC binding experiments with natural and synthetic lacticin 3147 analogues and phospholipid LUVs containing 1 mol% 
Gram-positive lipid II. (A) Lipid II added to LtnA1.  (B) LtnA1 added to LtnA2. (C) Lipid II added to 1:1 LtnA1:LtnA2. (D) 
LtnA1 added to desMe-LtnA2. (E) LtnA1 added to oxa-LtnA2. (F) Lipid II added to 1:1 LtnA1:desMe-LtnA2. (G) Lipid II added 
to 1:1 LtnA1:oxa-LtnA2. Binding enthalpy (Kd) and number of binding sites (N) are shown.  
peptides, as well as synergistic mixtures, and Gram-
positive lipid II. Gram-positive lipid II often contains 
lysine in its pentapeptide, whereas Gram-negative lipid II 
usually contains diaminopimelic acid. To better mimic a 
Gram-positive bacterial membrane, 1 mol% lipid II 
(containing a lysine residue) was incorporated into large 
unilamellar vesicles (LUVs) for the ITC experiments. In 
these LUVs, lipid II is symmetrically distributed between 
the inner and outer leaflets, and cannot translocate the 
artificial membrane without a flippase. Therefore, the 
actual concentration of lipid II present on the outer leaflet 
is 0.5 mol%.26 LtnA1 binds to membrane-embedded lipid 
II in a 2:1 ratio with a binding affinity (kD) of 0.9 M, 
which is consistent with its minimum inhibitory 
concentration (1 M) (Figure 2A). However, none of the 
LtnA2 analogues bind to lipid II (Figure S1). Given the 
synergistic relationship between LtnA1 and LtnA2, the 
binding interaction between these peptides was also 
assessed by ITC. LtnA1 binds strongly to LtnA2 in a 1:1 
ratio with a kD of 1.2 M (Figure 2B). When lipid II 
LUVs were added to a 1:1 mixture of LtnA1:LtnA2, the 
binding isotherm changed (Figure 2C). The resulting 
isotherm is characteristic of a heterotropic interaction, in 
which cooperative binding occurs between a 
macromolecule (LtnA1) and two different ligands (LtnA2 
and lipid II).27 Therefore it is not accurate to measure the 
number of binding sites or binding affinity by this method 
as it only gives an average of the various possible binding 
states between LtnA1, LtnA2 and lipid II embedded in 
the LUVs. The binding of LtnA1 to synthetic LtnA2 
analogues was also tested, and it was found that LtnA1 
binds weakly to desMe-LtnA2 (Figure 2D) and does not 
bind to oxa-LtnA2 at all (Figure 2E). These 
measurements are consistent with our previous 
observations that desMe-LtnA2 has reduced synergistic 
activity with LtnA1 but oxa-LtnA2 is not synergistic with 
LtnA1.21,22 The binding of LtnA1 + des-LtnA2 to lipid II 
(Figure 2F) and LtnA1 + oxa-LtnA2 to lipid II (Figure 
2G) were then analyzed. The resulting curves are very 
similar to LtnA1 + LtnA2 + lipid II (Figure 2C). In the 
case of oxa-LtnA2 this is surprising, given that it does not 
bind to LtnA1. It is possible that upon formation of the 
LtnA1:lipid II complex, oxa-LtnA2 is then able to bind to 
this structure. However, at this stage further experiments 
were required to determine how these binding studies 
relate to antimicrobial activity. 
 
  
Figure 3. (A) Cartoon schematic of the assay used to assess membrane lysis of the lacticin 3147 analogues. (B) Relative 
fluorescence vs. time graph showing the effects of adding lacticin 3147 analogues to LUVs containing BCECF. Peptide 
concentrations are 5 M. (C) Relative fluorescence vs. time graph showing the effects of adding lacticin 3147 analogues to LUVs 
doped with 1 mol% lipid II and containing BCECF. Peptide concentrations are 100 nM. 
In vitro membrane lysis assays 
To link the ITC results to the effect on cell membranes, a 
series of pore-formation assays were performed using 
LUVs containing the pH sensitive dye 2′,7′-bis-(2-
carboxyethyl)-5-carboxy-fluorescein (BCECF).28 In this 
assay, LUVs are constructed with an internal pH of 8 and 
then placed in buffer at pH 6. If pore formation occurs, 
there is a decrease in intra-vesicle pH, which is observed 
as a decrease in BCECF fluorescence (Figure 3A).10,28 To 
assess the effect of membrane bound lipid II on 
membrane lysis, LUVs with and without lipid II were 
constructed. In LUVs lacking lipid II, no membrane lysis 
was observed for any of the lacticin 3147 analogues at 
concentrations up to 5 M (Figure 3B). However, a 1:1 
mixture of LtnA1:LtnA2 caused rapid membrane lysis. 
The synergistic mixture of LtnA1:desMe-LtnA2 caused a 
smaller degree of membrane lysis in vesicles lacking lipid 
II, however no effect was observed for LtnA1:oxa-LtnA2. 
These results are consistent with the ITC studies, which 
showed that oxa-LtnA2 does not bind to LtnA1. When 
lipid II was incorporated into the LUVs, the concentration 
of 1:1 LtnA1:LtnA2 or 1:1 LtnA1:desMe-LtnA2 required 
for membrane lysis dropped significantly to 100 nM 
(Figure 3C). Consistent with the absence of lipid II 
binding found during the ITC studies, none of the LtnA2 
analogues caused membrane lysis. In contrast, LtnA1, 
which was shown by ITC to bind to lipid II, causes 
moderate membrane lysis at 100 nM. These results show 
that although lacticin 3147 can cause membrane lysis 
without lipid II, the presence of lipid II significantly 
enhances activity. An anomaly observed during the ITC 
studies was the binding curve for 1:1 LtnA1:oxa-LtnA2 + 
lipid II. Even though oxa-LtnA2 does not bind to LtnA1, 
the binding curve was nearly identical to the synergistic 
mixture of the natural peptides + lipid II, suggesting a 
similar interaction. However, the degree of membrane 
lysis observed for 1:1 LtnA1:oxa-LtnA2 is identical to 
LtnA1 alone, showing that the major interaction resulting 
in the ITC binding curve is LtnA1 binding to lipid II. 
Having linked lipid II binding to membrane lysis, we next 
sought to relate this to antimicrobial activity. 
Time-kill assays 
Time-kill assays are often used to determine if an 
antibiotic is bacteriostatic or bactericidal.10 In these 
experiments, Lactococcus lactis subsp. cremoris HP cells 
were incubated in the presence of set concentrations of 
lacticin 3147 peptides (1 μM or 250 nM) for 8 hours. At 
certain time points, an aliquot of bacterial suspension was 
removed, spread on an agar plate and grown overnight. 
The number of colony forming units (CFUs) per mL were 
then counted and plotted over the course of the 8-hour 
experiment (Figure 4A and B). In a time-kill assay, 
bacteriostatic agents (e.g. chloramphenicol) are easily 
identified, as the number of CFUs will remain constant 
over the time-course of the experiment. Bactericidal 
agents kill cells, therefore the number of CFUs will 
decrease over time if cells are exposed to a bactericidal 
compound. Furthermore, membrane lysing agents cause 
rapid cell death, with the number of CFUs typically being 
reduced to 0 within 30 min. At both 250 nM and 1 μM, 
LtnA1 halted cell-growth but did not significantly reduce 
the number of CFUs over an 8-hour period. This shows 
that LtnA1 binding to lipid II exerts a bacteriostatic 
effect. In contrast, LtnA2 is bactericidal. At 250 nM all 
cells are killed over the 8-hour time-course, however at 1 
μM the time taken to kill all cells is reduced to 30 min. 
This suggests that at higher concentrations, LtnA2 alone 
can kill Gram-positive bacteria by lysis of the cell 
membrane. In the in vitro membrane lysis assay, LtnA2 
showed no lytic activity against LUVs with or without 
lipid II. Therefore, these artificial membranes either lack 
the lipid composition required for LtnA2 induced 
membrane lysis, or LtnA2 binds to a membrane 
embedded biomolecule that is not present in the LUVs. 
To confirm this, an in vivo membrane lysis assay was 
required (next page). The synergistic mixture of LtnA1 
and LtnA2 kills all cells within 10 min at 250 nM and 5 
min at 1 μM, which is highly suggestive of rapid 
membrane lysis. These results corroborate that the 
synergistic mixture of LtnA1 and LtnA2 kills Gram-
positive bacteria by rapid membrane lysis. To confirm 
these findings in vivo, SYTOX Green membrane lysis 
assays were performed. 
  
Figure 4. Time-kill assays. Lactococcus lactis subsp. cremoris 
HP cells treated with 250 nM (A) or 1 μM (B) of peptide and 
the number of viable cells determined at different time points. 
In vivo membrane lysis assays 
To assess the effect of lacticin 3147 peptides on whole-
cell membranes, in vivo membrane lysis assays were 
performed using SYTOX Green (Figure 5). SYTOX 
Green is a membrane-impermeable reagent that 
penetrates cells with compromised cell membranes, 
binding to nucleic acids and emitting a fluorescent 
signal.29 Lactococcus lactis subsp. cremoris HP cells were 
incubated with SYTOX Green and peptides were then 
added to a final concentration of 100 nM. Nisin (1) is 
known to cause rapid pore-formation at this 
concentration, and indeed showed rapid membrane lysis 
in the SYTOX Green assay. LtnA1 did not cause 
membrane lysis, which is consistent with the previous 
experiments in this study. The synergistic mixture of 
LtnA1 and LtnA2 caused immediate membrane lysis, 
although not to the same extent as nisin. Gratifyingly, 
LtnA2, which did not cause membrane lysis in the in vitro 
assay but showed bactericidal kinetics consistent with a 
lytic peptide, caused membrane lysis in this whole-cell 
experiment. This provides further evidence that either the 
artificial membranes lack the lipid content required for 
LtnA2 lysis, or they lack a membrane embedded 
biomolecule that LtnA2 binds to induce membrane lysis. 
Solution NMR derived model of LtnA1:lipid II complex 
Having identified LtnA1 as a lipid II binding peptide, we 
next sought to identify how it binds using NMR 
experiments. Natural lipid II contains a long 
undecaprenyl chain (C55) that is not very amenable to 
NMR studies, as it has poor solubility and its multiple 
methylene units can 
cover
 
Figure 5. Lactococcus lactis subsp. cremoris HP cells pre-
treated with SYTOX green were exposed to antimicrobial 
peptides (100 nM) and the extent of membrane lysis visualized 
as an increase in fluorescence. 
 
important signals from the peptide. Therefore, a shorter 
chain version, (E,E)-farnesyl lipid II (9) was synthesized 
by adapting previously published methodology.10 
Glycosyl acceptor 10 was prepared in 5 steps and 
glycosyl donor 11 in 4 steps from commercially available 
starting materials.10 A TMSOTf catalyzed glycosylation, 
followed by protecting group manipulation, 
phosphorylation of the MurNAc anomeric position and 
deprotection of the 2-(phenylsulfonyl)ethyl ester with 
DBU gave acid 12 (Scheme 1). Coupling to deprotected 
Boc-tetrapeptide 13 (Scheme S1) then produced 
disaccharidyl pentapeptide 14 in 54% yield. Finally, 
deprotection of the dibenzyl phosphate moiety, followed 
by coupling to CDI activated (E,E)-farnesyl phosphate 
and HPLC purification yielded (E,E)-farnesyl lipid II (9) 
in 15% isolated yield. 
 
   
Scheme 1. Total synthesis of (E,E)-farnesyl lipid II (9). (a) 
TMSOTf, 4 Å MS, CH2Cl2, rt, 18 h, 61%. (b) (i) ZnCl2, 
AcOH/Ac2O, rt, 24 h; (ii) Zn, THF/AcOH/Ac2O, rt, 24 h, 63% 
(two steps). (c) (i) H2, Pd/C, MeOH, rt, 3 h; (ii) (
iPr)-
2NP(OBn)2, tetrazole, CH2Cl2, rt, 2 h; (iii) 30% H2O2 in THF, 
−78 °C to rt, 2 h, 84% (three steps). (d) DBU, CH2Cl2, rt, 0.5 
h, quant. (e) Boc-Tetrapeptide 13, TFA/CH2Cl2, 2h; NHS, 
EDCI.HCl, DMF, rt, 18 h, 54%. (f) (i) H2, Pd/C, MeOH, rt, 2.5 
h, (ii) CDI activated (E,E)-farnesyl phosphate, DMF, rt, 4d, 
(iii) NaOH, H2O/dioxane, 37°C, 2 h, 15% (three steps). 
    
    Extensive solvent screening identified 1:1:1 CD3-
OH:CD3CN:H2O as a suitable solvent for the NMR 
studies. LtnA1 and (E,E)-farnesyl lipid II were both 
characterized separately in this solvent system by 1H-
NMR, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY and 
31P-NMR (Tables S1-S2). The chemical shifts were then 
assigned in a 1:1 mixture of LtnA1 and (E,E)-farnesyl 
lipid II (Tables S3-S4). A significant chemical shift 
perturbation (~1.0 ppm) was observed in the 
pyrophosphate signals of lipid II when LtnA1 was added 
(Figure S2). To ensure this was a real effect and not due 
to a solvent/dielectric effect from high concentrations of 
peptide present, the same experiment was repeated with 
LtnA2. In this instance, no change in the 31P-NMR of 
lipid II occurred (Figure S3). Chemical shift perturbations 
also occurred in the amide protons of Ala1 and D-Glu2 as 
well as Lys3-Hβ (Figure S4). The largest 1H-chemical 
shift changes in LtnA1 were observed in the amide N-H 
signals of His23, Glu24, Cys25, Met26, Trp28, Cys29 and 
Lys30 (Figure S5). 7 intermolecular NOEs were also 
found (Figure S6), between D-Glu2 (lipid II) and Asn15, 
Cys19 and Abu20 (LtnA1), as well as Lys3 (lipid II) and 
Asn15 (LtnA1). The chemical shift assignments and NOE 
peak list from the LtnA1:lipid II complex were then used 
to generate a model of the complex using CYANA 
(Figure 6 and S7).30 Based on the observed 31P chemical 
shift perturbations and intermolecular NOEs, as well as 
the earlier work of Sahl et al,13d four loose artificial NOE 
restraints were introduced involving residues Glu24 and 
Lys30 with both phosphate atoms for relative anchoring 
of LtnA1 and lipid II. The resulting CYANA generated 
model is consistent with all intermolecular NOEs and 
chemical shift perturbations. 
   LtnA1 binds to the pyrophosphate and pentapeptide 
moieties of lipid II (Figure 6A). Closer analysis of the 
structure revealed the D-ring (res. 22-30) of LtnA1 forms 
a hydrophilic groove that binds to the pyrophosphate on 
lipid II (Figure 6B). The LtnA1:lipid II complex was 
analyzed in MacPyMol to identify intermolecular 
interactions between LtnA1 and lipid II. The amide 
protons of Glu24, Cys25, Met26 and Lys30 form 
hydrogen bonds with the phosphate oxygen atoms in lipid 
II (Figure 6C). Furthermore, the electron deficient 
imidazole ring on His23 forms a pi-anion bond31 (pi-
clamp) with a P-O oxygen anion in lipid II, as well as a 
H-bond. Chemical shift perturbations were found in all of 
these LtnA1 residues, further supporting the CYANA 
generated LtnA1:lipid II complex. 
Comparison to other lipid II binding lantibiotics 
Having identified that LtnA1 binds to the pyrophosphate 
of lipid II, we next sought to compare this binding 
mechanism to other lipid II-binding lantibiotics (Figure 
7). The NMR solution structure of the nisin:lipid II 
complex was previously determined in DMSO.13d This 
Type-A(I) lantibiotic adopts an elongated structure in 
which the N-terminal residues bind to lipid II (Figure 
7A). In contrast, as a Type-B-like lantibiotic, LtnA1 
adopts a globular structure, with lipid II binding occurring 
at the C-terminus (Figure 7B). The pyrophosphate cage 
adopted by nisin (Figure 7D) is shallower than that 
adopted by LtnA1 (Figure 7E), with binding occurring 
exclusively through amide intermolecular hydrogen 
bonds. As well as intermolecular hydrogen bonding, 
LtnA1 also uses an interesting pi-clamp interaction to 
bind to the lipid II pyrophosphate. For both nisin and 
LtnA1, the major interaction is with the lipid II 
pyrophosphate.  The NMR solution structure of 
mersacidin (2) was previously determined in DPC 
micelles containing Gram-positive lipid II.14b However, 
the NMR solution structure adopted by lipid II in this 
complex was not determinable. Mersacidin has 
significantly higher affinity for lipid II than lipid I (which 
lacks GlcNAc)32 and has increased activity in calcium 
enriched media.33 These findings suggest that mersacidin 
may bind to both the pyrophosphate and GlcNAc 
moieties in lipid II. In the absence of a structure of the 
mersacidin:lipid II complex, lipid II analogue 9 was
 
 
Figure 6. (A) Model of the complex formed between LtnA1 and (E,E)-farnesyl lipid II. LtnA1 is shown as a surface representation 
with hydrophobic residues green and hydrophilic residues yellow. Lipid II is represented as a stick model. LtnA1 binds mainly to 
the pyrophosphate and pentapeptide regions of lipid II. (B) The pyrophosphate binding pocket of LtnA1 as a surface representation. 
(C) Key binding interactions between the C-terminal residues of LtnA1 and pyrophosphate of lipid II. H-bonds between the lipid II 
pyrophosphate and the amide protons of Glu24, Cys25, Met26 and Lys30 were identified (yellow dash), as well as a possible pi-
anion interaction (turquoise dash) and H-bond between the lipid II pyrophosphate and the imidazole ring of His23. 
  
Figure 7. (A) NMR solution structure of the nisin-lipid II complex (1WCO), (B) Model of the LtnA1-lipid II complex and (C) 
Lipid II docked into the NMR solution structure of mersacidin bound to lipid II in DPC micelles (1MQZ). In (A) – (C) peptides are 
shown as a surface representation with hydrophobic residues green and hydrophilic residues yellow, and lipid II is represented as a 
stick model. Nisin adopts an elongated structure and binds to lipid II with its N-terminal residues, whereas both LtnA1 and 
mersacidin adopt a globular structure and bind to lipid II through their C-terminal residues. (D) The nisin-lipid II pyrophosphate 
cage, (E) the LtnA1-lipid II cage and (F) a model of the proposed mersacidin-lipid II intermolecular bonds. In (D) – (F) the peptide 
backbone is shown a stick model wherein carbon = green, oxygen = red, nitrogen = blue and sulfur = yellow, and some side-chain 
residues have been included. The pyrophosphate moiety within lipid II is represented by spheres with the rest of lipid II omitted for 
clarity, unless needed to show key intermolecular bonds. Nisin forms a tight pyrophosphate cage with several intermolecular 
hydrogen bonds, whereas the LtnA1 pyrophosphate cage is looser, with less intermolecular hydrogen-bonds but with a pi-clamping 
interaction. The mersacidin-lipid II model suggests hydrogen-bonding between Glu-17 and both the pyrophosphate and GlcNAc 
moieties of lipid II and is supported by all experimental evidence of mersacidin-lipid II binding to date.
docked into the NMR solution structure of mersacidin 
using AutoDock Vina (Figure 7C and F).34 This Type-B 
lantibiotic adopts a globular structure similar to LtnA1. 
In the resulting model, the C-terminal residues of 
mersacidin that have previously been shown to interact 
with lipid II are involved in lipid II binding. There are 
predicted intermolecular H-bonds between the amides 
of Dha16 and Glu17 and the pyrophosphate, as well as 
the carboxylate group of Glu17 and GlcNAc. Glu17 was 
previously shown be very important in the antimicrobial 
activity of mersacidin, with mutation of this residue to 
alanine abolishing activity.18 Care must be taken when 
comparing the structures of nisin, LtnA1 and mersacidin 
bound to lipid II, as they were calculated in different 
solvents. Ideally these would be calculated in the same 
solvent system for comparison, however this is not 
possible due to the differing solubility’s of the 
respective peptide:lipid II complexes. 
   Haloduracin is another two-component lantibiotic, 
composed of Type-B-like (Halα, (3)) and Type-A(I)-like 
(Halβ (4)) peptides.16a Analogues to the lacticin 3147 
peptides, Halα and Halβ operate synergistically in a 1:1 
ratio to kill Gram-positive bacteria. Previous studies 
have also shown that Halα inhibits the 
transglycosylation reaction between lipid II and 
penicillin-binding protein 1b (PBP1b) by binding to 
lipid II in a 2:1 ratio.35 These findings suggest a 2:2:1 
Halα:Halβ:lipid II complex is formed, which inhibits 
cell wall biosynthesis and mediates pore formation. 
Previous studies on the nisin:lipid II binding interaction 
by ITC showed a 1:1 binding ratio, however further in 
vivo studies using fluorescently labelled lipid II 
suggested a 2:1 nisin:lipid II ratio in the resulting 
complex formed.36 Like Halα and nisin, our studies 
suggest that LtnA1 binds to lipid II in a 2:1 ratio. 
Furthermore, given the 1:1 synergistic activity of LtnA1 
and LtnA2, our results suggest that lacticin 3147 exerts 
its antimicrobial effect by a similar mechanism to 
haloduracin - by forming a 2:2:1 LtnA1:LtnA2:lipid II 
complex, that results in rapid membrane lysis by pore 
formation. 
CONCLUSIONS 
In this article we have shown that the lantibiotic lacticin 
3147 can kill Gram-positive bacteria by several 
mechanisms of action. The type-B-like component of 
lacticin 3147, LtnA1, is bacteriostatic and does not form 
pores in the bacterial membrane. Instead, LtnA1 binds 
 to the peptidoglycan precursor lipid II in a 2:1 ratio by 
formation of a “pyrophosphate cage” using its C-
terminal residues, which likely inhibits peptidoglycan 
biosynthesis. The other component, LtnA2, is 
bactericidal at micromolar concentrations, killing 
bacteria by membrane lysis. Co-administration of both 
LtnA1 and LtnA2 causes rapid lysis in artificial 
membranes without lipid II, indicating direct pore 
forming activity by this peptide combination. However, 
the presence of lipid II greatly enhances this activity. 
These results provide valuable insight into the 
mechanism of action of lipid II-binding lantibiotics, as 
now at least three (nisin, haloduracin and lacticin 3147) 
are known to bind to lipid II in a 2:1 ratio. Analogous to 
the mechanism of action of haloduracin, lacticin 3147 
appears to form a 2:2:1 peptide A:peptide B:lipid II 
complex, that results in rapid membrane lysis by pore 
formation. LtnA1 and Halα both bind to lipid II on the 
surface of the cell membrane and then direct their 
partner peptide to the membrane to kill bacteria. This 
may allow for the delivery of different antimicrobial 
compounds across the cell membrane, as has been 
shown for other antimicrobial peptides.37 Although we 
now have a detailed understanding of how lacticin 3147 
interacts with lipid II, the synergistic interaction 
between LtnA1 and LtnA2 at the molecular level is less 
well understood. Further studies are ongoing in this 
area. 
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